This page summarizes product characteristics used in clinical research and explains how to interpret supplement labels. It is intended for educational purposes. Any future product evaluations or commercial relationships will be clearly disclosed.
Why Extract Standardization Matters
Most Boswellia serrata supplements describe themselves as "boswellia extract" without specifying type or standardization. This matters because clinical trials used specific, standardized extracts — and results from those trials may not apply to products with different compositions. Key variables include: total boswellic acid content, AKBA percentage, presence of a proprietary enhanced-bioavailability formulation, and the species of Boswellia used.
What Clinical Trials Used
Standard Boswellic Acid Extracts
Older clinical trials typically used extracts described as containing 60–65% total boswellic acids, at doses of 300–500 mg two to three times daily.
AKBA-Enriched Formulations
More recent clinical trials — particularly in osteoarthritis — used proprietary AKBA-enriched extracts: Aflapin® (standardized to ≥20% AKBA) and 5-Loxin® (standardized to 30% AKBA). These formulations were developed to improve bioavailability. Most trials using these formulations used lower doses (100–250 mg/day) than trials using standard extracts. AprèsFlex® is a reformulation of Aflapin® used in some trials.
What to Look for on a Label
- Species identification: Should specify Boswellia serrata. Generic "boswellia" does not guarantee species identity.
- Standardization percentage: Total boswellic acid content or AKBA percentage. Products without standardization claims cannot be compared to trial evidence.
- Proprietary extract name: If the product uses Aflapin®, 5-Loxin®, or AprèsFlex®, it can be compared to trials using those specific formulations.
- Dose and serving size: Compare to dose ranges used in clinical trials. See the Dosage Guide.
- Third-party testing: Some products publish third-party testing data verifying boswellic acid content.
Extract Composition Varies Widely
Two products both labeled "Boswellia serrata 500 mg" may have substantially different boswellic acid profiles, AKBA content, and bioavailability characteristics. Clinical trial results obtained with a specific standardized extract cannot be assumed to apply to unstandardized or differently standardized products.
References
- 1Sengupta K, et al. (2010). A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Research and Therapy. PubMed ↗
- 2Abdel-Tawab M, et al. (2011). Boswellia serrata: pharmacokinetic and clinical data. Clinical Pharmacokinetics. PubMed ↗